Skip to content

Study · In silico · 2024

9 results

5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.

Niu S, Alkhuzam KA, Guan D, Jiao T, Shi L, Fonseca V, Laiteerapong N, Ali MK, Schatz DA, Guo J, Shao H

Diabetes, obesity & metabolism22 Oct 2023Cited by 9 (Europe PMC)

PMID37867175 (opens in a new tab)PMCIDPMC11115367 (opens in a new tab)DOI10.1111/dom.15332 (opens in a new tab)PepBankPUB-37867175
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01Computer modelIn silicoEfficacy outcome

    In a simulation of adults with type 2 diabetes, 15 mg tirzepatide lowered projected 5-year cardiovascular adverse events versus insulin glargine (rate ratio 0.64) in the optimistic scenario.

    In plain wordsA computer simulation projected that tirzepatide 15 mg lowers 5-year heart and blood vessel events versus insulin glargine.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProjected 5-year cardiovascular adverse events, tirzepatide 15 mg versus insulin glargine (optimistic)
    Study

    n: not reported in source

    BRAVO diabetes simulation model
    Comparator
    Insulin glargine
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    15 mg · 5 years (simulated)As given in this study.

    Measurements

    Rate ratio
    0.64
    tirzepatide 15 mg, optimistic
    95% CI
    0.61 to 0.67
    tirzepatide 15 mg, optimistic

    Source sentences

    Summary
    we projected a 5-year risk reduction in cardiovascular adverse events [rate ratio (RR) 0.64, 95% confidence interval (CI) 0.61-0.67]
    2 context sentences
    Summary · context
    This study compared the 5-year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model.
    Summary · context
    We used the BRAVO model to predict 5-year complications for each study arm under two scenarios: the 1-year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative).
  2. 02Computer modelIn silicoEfficacy outcome

    In a simulation of adults with type 2 diabetes, 15 mg tirzepatide lowered the projected 5-year microvascular composite versus insulin glargine (rate ratio 0.67) in the optimistic scenario.

    In plain wordsA computer simulation projected that tirzepatide 15 mg lowers 5-year small blood vessel complications versus insulin glargine.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProjected 5-year microvascular composite, tirzepatide 15 mg versus insulin glargine (optimistic)
    Study

    n: not reported in source

    BRAVO diabetes simulation model
    Comparator
    Insulin glargine
    Outcome group
    Diabetes complications · Whole body
    Studied dose
    15 mg · 5 years (simulated)As given in this study.

    Measurements

    Rate ratio
    0.67
    tirzepatide 15 mg, optimistic
    95% CI
    0.64 to 0.7
    tirzepatide 15 mg, optimistic

    Source sentences

    Summary
    microvascular composite (RR 0.67, 95% CI 0.64-0.70)
    2 context sentences
    Summary · context
    This study compared the 5-year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model.
    Summary · context
    We used the BRAVO model to predict 5-year complications for each study arm under two scenarios: the 1-year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative).
  3. 03Computer modelIn silicoEfficacy outcome

    In a simulation of adults with type 2 diabetes, semaglutide 1 mg lowered projected 5-year cardiovascular adverse events versus insulin glargine (rate ratio 0.75) in the optimistic scenario.

    In plain wordsA computer simulation projected that semaglutide 1 mg lowers 5-year heart and blood vessel events versus insulin glargine.

    Peptide
    Semaglutide
    Outcome
    DecreaseProjected 5-year cardiovascular adverse events, semaglutide 1 mg versus insulin glargine (optimistic)
    Study

    n: not reported in source

    BRAVO diabetes simulation model
    Comparator
    Insulin glargine
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1 mg · 5 years (simulated)As given in this study.

    Measurements

    Rate ratio
    0.75
    semaglutide 1 mg, optimistic
    95% CI
    0.72 to 0.79
    semaglutide 1 mg, optimistic

    Source sentences

    Summary
    cardiovascular adverse events (RR 0.75, 95% CI 0.72-0.79)
    2 context sentences
    Summary · context
    This study compared the 5-year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model.
    Summary · context
    We used the BRAVO model to predict 5-year complications for each study arm under two scenarios: the 1-year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative).
  4. 04Computer modelIn silicoEfficacy outcome

    In a simulation of adults with type 2 diabetes, semaglutide 1 mg lowered the projected 5-year microvascular composite versus insulin glargine (rate ratio 0.79) in the optimistic scenario.

    In plain wordsA computer simulation projected that semaglutide 1 mg lowers 5-year small blood vessel complications versus insulin glargine.

    Peptide
    Semaglutide
    Outcome
    DecreaseProjected 5-year microvascular composite, semaglutide 1 mg versus insulin glargine (optimistic)
    Study

    n: not reported in source

    BRAVO diabetes simulation model
    Comparator
    Insulin glargine
    Outcome group
    Diabetes complications · Whole body
    Studied dose
    1 mg · 5 years (simulated)As given in this study.

    Measurements

    Rate ratio
    0.79
    semaglutide 1 mg, optimistic
    95% CI
    0.76 to 0.82
    semaglutide 1 mg, optimistic

    Source sentences

    Summary
    microvascular composite (RR 0.79, 95% CI 0.76-0.82)
    2 context sentences
    Summary · context
    This study compared the 5-year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model.
    Summary · context
    We used the BRAVO model to predict 5-year complications for each study arm under two scenarios: the 1-year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative).
  5. 05Computer modelIn silicoEfficacy outcome

    In a simulation of adults with type 2 diabetes, lower tirzepatide doses also gave similar but smaller projected benefits than 15 mg versus insulin glargine.

    In plain wordsA computer simulation projected similar but smaller benefits with lower tirzepatide doses than with the 15 mg dose.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProjected complications, lower tirzepatide doses versus insulin glargine
    Study

    n: not reported in source

    BRAVO diabetes simulation model
    Comparator
    Insulin glargine
    Outcome group
    Diabetes complications · Whole body
    Studied dose
    5 or 10 mg · 5 years (simulated)As given in this study.

    Source sentences

    Summary
    Lower doses of tirzepatide also had similar, albeit smaller benefits.
    2 context sentences
    Summary · context
    This study compared the 5-year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model.
    Summary · context
    We used the BRAVO model to predict 5-year complications for each study arm under two scenarios: the 1-year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative).
  6. 06Computer modelIn silicoEfficacy outcome

    In a simulation of adults with type 2 diabetes, tirzepatide effects were smaller but still significantly better than insulin glargine under the conservative scenario.

    In plain wordsA computer simulation projected that tirzepatide still beats insulin glargine under cautious assumptions, with smaller benefits.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProjected complications, tirzepatide versus insulin glargine (conservative)
    Study

    n: not reported in source

    BRAVO diabetes simulation model
    Comparator
    Insulin glargine
    Outcome group
    Diabetes complications · Whole body
    Studied dose
    5, 10 or 15 mg · 5 years (simulated)As given in this study.

    Source sentences

    Summary
    Treatment effects for tirzepatide and semaglutide were smaller but still significantly higher than insulin glargine under a conservative scenario.
    2 context sentences
    Summary · context
    This study compared the 5-year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model.
    Summary · context
    We used the BRAVO model to predict 5-year complications for each study arm under two scenarios: the 1-year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative).
  7. 07Computer modelIn silicoEfficacy outcome

    In a simulation of adults with type 2 diabetes, semaglutide effects were smaller but still significantly better than insulin glargine under the conservative scenario.

    In plain wordsA computer simulation projected that semaglutide still beats insulin glargine under cautious assumptions, with smaller benefits.

    Peptide
    Semaglutide
    Outcome
    DecreaseProjected complications, semaglutide versus insulin glargine (conservative)
    Study

    n: not reported in source

    BRAVO diabetes simulation model
    Comparator
    Insulin glargine
    Outcome group
    Diabetes complications · Whole body
    Studied dose
    1 mg · 5 years (simulated)As given in this study.

    Source sentences

    Summary
    Treatment effects for tirzepatide and semaglutide were smaller but still significantly higher than insulin glargine under a conservative scenario.
    2 context sentences
    Summary · context
    This study compared the 5-year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model.
    Summary · context
    We used the BRAVO model to predict 5-year complications for each study arm under two scenarios: the 1-year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative).
  8. 08Computer modelIn silicoEfficacy outcome

    In a simulation of adults with type 2 diabetes, 15 mg tirzepatide gave a projected 10% to 49% 5-year risk reduction in complication events and mortality versus insulin glargine in the optimistic scenario.

    In plain wordsA computer simulation projected that tirzepatide 15 mg cuts 5-year complication and death risk by 10% to 49% versus insulin glargine.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProjected 5-year risk reduction in complications and mortality, tirzepatide 15 mg (optimistic)
    Study

    n: not reported in source

    BRAVO diabetes simulation model
    Comparator
    Insulin glargine
    Outcome group
    Diabetes complications · Whole body
    Studied dose
    15 mg · 5 years (simulated)As given in this study.

    Measurements

    Risk reduction
    10 to 49%
    tirzepatide 15 mg, optimistic

    Source sentences

    Summary
    The 5-year risk reduction in diabetes-related complication events and mortality for the 15 mg tirzepatide compared with insulin glargine ranged from 49% to 10% under an optimistic scenario
    2 context sentences
    Summary · context
    This study compared the 5-year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model.
    Summary · context
    We used the BRAVO model to predict 5-year complications for each study arm under two scenarios: the 1-year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative).
  9. 09Computer modelIn silicoEfficacy outcome

    In a simulation of adults with type 2 diabetes, the projected 5-year risk reduction with 15 mg tirzepatide was lowered by 17% to 33% under the conservative scenario.

    In plain wordsIn a computer simulation, the projected benefit of tirzepatide 15 mg became 17% to 33% smaller under cautious assumptions.

    Peptide
    Tirzepatide
    Outcome
    DecreaseReduction of projected benefit under the conservative scenario, tirzepatide 15 mg
    Study

    n: not reported in source

    BRAVO diabetes simulation model
    Comparator
    Insulin glargine
    Outcome group
    Diabetes complications · Whole body
    Studied dose
    15 mg · 5 years (simulated)As given in this study.

    Measurements

    Reduction of risk reduction
    17 to 33%
    conservative scenario

    Source sentences

    Summary
    which was reduced by 17%-33% when a conservative scenario was assumed.
    3 context sentences
    Summary · context
    The 5-year risk reduction in diabetes-related complication events and mortality for the 15 mg tirzepatide compared with insulin glargine ranged from 49% to 10% under an optimistic scenario, which was reduced by 17%-33% when a conservative scenario was assumed.
    Summary · context
    This study compared the 5-year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model.
    Summary · context
    We used the BRAVO model to predict 5-year complications for each study arm under two scenarios: the 1-year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.